Dennis Kim has joined Sesen Bio (NASDAQ: [[ticker:SESN]]) as the Cambridge, MA, biotech’s chief medical officer. Kim’s experience includes posts at Ipsen, Spectrum Pharmaceuticals, Novartis (NYSE: [[ticker:NVS]]), and Amgen (NASDAQ: [[ticker:AMGN]]). Sesen was originally founded as Eleven Biotherapeutics. The company’s most advanced drug candidate, VB4-845, is in late-stage studies testing it as a treatment for bladder cancer.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
